First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
Clinical trial NCT04396340 · TERMINATED
Trial details
- NCT number
- NCT04396340
- Sponsor
- Mersana Therapeutics
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-11
- Primary completion
- 2022-09-30
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.